Activation of proteasomes via this mechanism may be useful in treating proteotoxic diseases since PKA activation stimulated the degradation of various aggregation-prone proteins, including mutant FUS (Fused in sarcoma), SOD1 (superoxide dismutase 1), TDP43 (TAR DNA-binding protein 43), and tau [155], and reduced the levels of aggregated tau protein and improved cognitive function in a mouse model of tautopathy [156]. This evidence concerns the gene MAPT and sarcoma.